Heart failure & cardiomyopathies
Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy
Authors' conclusion
This study identified circulating biomarkers that distinguish HCM from other cardiomyopathies with LVH independently from confounders and revealed signaling pathways associated with HCM.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) or other cardiomyopathies with left ventricular hypertrophy (LVH); plasma proteomics profiling4,979 proteins analysed
- Participants
- 1,415 patients
- Comparison
- HCM vs other cardiomyopathies with LVH
- HCMn = 879
- Hypertensive LVHn = 331reference
- Transthyretin amyloid cardiomyopathyn = 169reference
- ASn = 36reference
- Outcome
- Circulating protein biomarkers distinguishing HCM from controls (logistic regression model AUC)
Methodological detailsmulticentre, training and test sets
- Multicentre
- Training and test sets
Main finding
As reported in the abstract
Discrimination of HCM vs controls by 5-protein logistic regression model
Candidate proteins selected
5
AUC of 5-protein model in test set
0.86
95% CI 0.82–0.89
Observational data: associations, not effects.
Further findings
Pathway analysis
- MAPK and HIF-1 pathways dysregulated in HCM throughout the 3 comparisons
Original publication
Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy. Circ Heart Fail. Published 11 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →